A study of Scemblix for newly diagnosed chronic myeloid leukemia in China
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at how well the medicine Scemblix (asciminib) works for people in China who have just been diagnosed with a certain type of leukemia (chronic myeloid leukemia in chronic phase). It aims to see if starting this treatment soon after diagnosis is effective and safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have been newly diagnosed with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) within the last 3 months.
- You can have taken certain other leukemia medicines (like interferon or hydroxyurea), but if you took a targeted therapy called a TKI, it must have been for no more than 2 weeks.
- You need to start taking the study drug Scemblix within 14 days of signing the consent form.
- You cannot have had a more advanced form of CML (accelerated phase or blast crisis) or other active cancers.
- Women who are pregnant, breastfeeding, or planning pregnancy cannot join.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at using asciminib in people with Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML) who are taking Scemblix. If you already use Scemblix, the study may test whether switching or adding asciminib is safe and helpful for managing your leukemia.
This study tests a targeted pill called asciminib for people newly diagnosed with chronic-phase CML. It aims to see if this drug is safe and effective as an early treatment option.
This study is watching how well asciminib (Scemblix) works in real life for people with chronic-phase CML in Saudi Arabia. If you've already tried two or more targeted therapies (TKIs) and recently started asciminib, this study may help doctors understand more about its effectiveness and side effects.
This study tests whether the drug asciminib is safe and works well for people with chronic myeloid leukemia, compared to standard TKIs. You may join if you're newly diagnosed or have tried only one previous TKI treatment.
This study looks at how well asciminib works in real-world patients with chronic myeloid leukemia who have already tried at least one other treatment. It aims to see how effective and safe it is in everyday practice.
This trial tests the drug asciminib for people newly diagnosed with chronic myeloid leukemia (CML) who have been on treatment for less than a month. It aims to see if early treatment with asciminib is safe and effective.
Hear when a new Chronic Myeloid Leukemia in Chronic Phase trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.